Every tumour is unique

Coming soon – our research tools could help scientists explore that diversity.

By studying Circulating Tumour Cells (CTCs) from a single blood sample, investigators can gain real-time data to advance understanding of cancer biology and explore new approaches. This might one day support precision medicine.

WHAT WE DO

Frontier Diagnostics is looking at redefining how researchers study cancer biology. With our advanced liquid biopsy platform, we are developing tools to capture and analyse circulating tumour cells (CTCs), opening new opportunities to investigate tumour dynamics at stages that may precede conventional methods of detection. Our research solutions will empower scientists to explore the potential for earlier insights and more individualised approaches in oncology.

WHY IT MATTERS

arrow
RESEARCH INTO PERSONALISED APPROACHES

Unlocking the potential to research how therapies might be matched to individual patient profiles—even before treatment begins. Research into circulating tumour cells (CTCs) is opening new avenues to investigate tumour biology and therapeutic response.

lightning
Fast, Non-Invasive Tests – coming soon

No biopsies. Just a simple blood draw.

continuous
Continuous Monitoring

Explore the potential to study tumour dynamics in real time and provide researchers with new insights that may inform future approaches in oncology. The tests, which will soon be available as  Research Use Only, however registration as IVD is in progress.

SERVICES

IN-HOUSE SAMPLE PROCESSING (RESEARCH USE ONLY)

For participating research sites, samples can be submitted to our laboratory for processing and return of research data within approximately 5 working days.

ON-SITE RESEARCH ANALYSIS (COMING SOON)

Larger laboratories and research sites will be able to use our Quantum FluoScope device for same-day on-site sample analysis under research use conditions.

BACKED BY EXPERTS

We’re not just advancing research tools- we’re working to rewrite the timeline of cancer understanding.

Dr. Martin Burow, CEO